Key result
Wide mastectomy plus adjuvant paclitaxel is linked to 12-month recurrence-free survival in a radiation-associated breast angiosarcoma case.
Why the study?
Radiation-associated angiosarcoma of the breast diagnosis is often delayed due to its rarity and nonspecific cutaneous manifestations, and no established treatment exists.
Case Report (n=41)
Radiation-associated angiosarcoma of the breast is a rare, serious complication of breast-conserving surgery and radiotherapy with delayed diagnosis and poor prognosis.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for radiation-associated breast angiosarcoma; leaves open optimal therapy in this rare poor-prognosis entity.
INTRODUCTION: Radiation-associated angiosarcoma of the breast (RAASB) is an extremely rare but serious complication that can occur several years after breast-conserving surgery and adjuvant radiotherapy. Owing to its rarity and nonspecific cutaneous manifestations, the diagnosis of RAASB is often delayed. There is no established treatment for RAASB, and its prognosis remains poor. CASE PRESENTATION: A 63-year-old woman developed progressive breast edema 14 years after breast-conserving surgery with axillary lymph node dissection and adjuvant radiotherapy for invasive ductal carcinoma. Two years later, she presented with breast masses with purpura and biopsy-confirmed angiosarcoma. Wide mastectomy with skin grafting was performed, followed by weekly administration of adjuvant paclitaxel. The patient remained recurrence-free for 12 months postoperatively. CONCLUSIONS: RAASB can develop long after breast-conserving therapy and may be preceded by subtle skin changes or persistent breast edema. Long-term follow-up and patient education are essential for patients who have undergone breast irradiation. Early imaging or biopsy should be considered when breast lymphedema is observed.
No takes yet. Share an insight, caveat, or question.
Ida et al. (2026) conducted a case report in Radiation-associated angiosarcoma of the breast (n=41). Mastectomy and adjuvant chemotherapy (paclitaxel) was evaluated on Recurrence-free survival. Wide mastectomy followed by adjuvant paclitaxel resulted in a 12-month recurrence-free period in a patient with radiation-associated breast angiosarcoma developing 16 years after initial treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: